Horizon Discovery signs key agreements with Cambridge Enterprise & University of Washington

12 Jul 2007

Horizon Discovery today announces the closing of two deals to progress the commercialisation of isogenic cell lines for the discovery and development of new anticancer agents.

Cambridge Enterprise Seed Funds (CESF) is supporting Horizon Discovery with a seed investment to market existing, and custom generated, isogenic cell-lines and supporting services to the pharmaceutical industry – the first commercial service of its kind in the world.

Additionally, The University of Washington has granted Horizon Discovery an exclusive license to a suite of patents that along with unique know-how of Horizon’s scientific founders is central to the efficient generation of X-MAN cell-lines using the virally-mediated gene targeting platform GENESIS.